2. Search Result
Search Result
Results for "

ATM kinase

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Screening Libraries

3

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12061
    KU-60019
    Maximum Cited Publications
    26 Publications Verification

    		 ATM/ATR Cancer
    KU-60019 is an improved ATM kinase-specific inhibitor with IC50 of 6.3 nM.
    KU-60019
  • HY-139609
    Camonsertib
    2 Publications Verification

    RP-3500; ATR inhibitor 4

    		 ATM/ATR mTOR Cancer
    Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .
    Camonsertib
  • HY-19959
    Mirin
    5+ Cited Publications

    		 ATM/ATR Apoptosis Cancer
    Mirin is a potent Mre11-Rad50-Nbs1 (MRN) complex inhibitor. Mirin prevents MRN-dependent activation of ATM (IC50=12 μM) without affecting ATM protein kinase activity, and it inhibits Mre11-associated exonuclease activity. Mirin abolishes the G2/M checkpoint and homology-dependent repair in mammalian cells. Mirin prevents ATM activation in response to DNA double-strand breaks (DSBs) and blocks homology-directed repair (HDR) in mammalian cells .
    Mirin
  • HY-157941
    ART0380

    		ATM/ATR Checkpoint Kinase (Chk) DNA/RNA Synthesis Cancer
    ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC50 of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .
    ART0380
  • HY-117693
    (E/Z)-Mirin
    5+ Cited Publications

    		 ATM/ATR Cancer
    (E/Z)-Mirin is a mixture of (E)-Mirin and Mirin ((Z)-Mirin) (HY-19959) configurations. Among them, Mirin is an inhibitor of MRN (Mre11-Rad50-Nbs1). Mirin prevents MRN-dependent ATM activation without affecting ATM protein kinase activity .
    (E/Z)-Mirin
  • HY-150617
    Lartesertib
    1 Publications Verification

    M4076; ATM Inhibitor-5

    		 ATM/ATR STING PD-1/PD-L1 Cardiovascular Disease Inflammation/Immunology Cancer
    Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .
    Lartesertib
  • HY-112198
    AZ31

    		ATM/ATR Cancer
    AZ31 is a a potent, highly selective, and orally active ATM inhibitor with an IC50 of <1.2 nM for ATM enzyme, and an IC50 of 46 nM for ATM in cell. AZ31 shows excellent selectivity over ATR (>500-fold) and excellent PIKK-family selectivity and pan-kinase selectivity. AZ31 is a potent radiosensitizer in vitro, it can be used for the research of cancer .
    AZ31
  • HY-11002
    CP-466722
    4 Publications Verification

    		 ATM/ATR Cancer
    CP-466722 is a rapidly reversible inhibitor of ATM, with an IC50 of 0.41 μM, and has no effects on PI3K or closely related PI3K-like protein kinase (PIKK) family members.
    CP-466722
  • HY-161615
    PROTAC ATR degrader-2

    		PROTACs ATM/ATR Apoptosis Inflammation/Immunology Cancer
    PROTAC ATR degrader-2 is a selective ATR PROTAC degrader. PROTAC ATR degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC50 values of 22.9 nM and 34.5 nM, respectively. PROTAC ATR degrader-2 has an IC50 of 29.6 nM against ATR, and its IC50 values against ATM and PI3K are both greater than 2000 nM. PROTAC ATR degrader-2 induces apoptosis, DNA damage, and upregulates p53 expression. PROTAC ATR degrader-2 inhibits cancer cell proliferation through the kinase-independent function of ATR protein. PROTAC ATR degrader-2 is applicable to research related to acute myeloid leukemia .
    PROTAC ATR degrader-2
  • HY-163944
    LL-K12-18

    		DNA/RNA Synthesis Molecular Glues CDK Apoptosis RAD51 ATM/ATR PARP Cancer
    LL-K12-18 is a CDK12 kinase inhibitor and a dual-site molecular glue. LL-K12-18 inhibits human CDK12 with an IC50 value of 283.9 nM, and selectively degrades cyclin K via the ubiquitin-proteasome system by stabilizing the CDK12-DDB1 complex. LL-K12-18 downregulates DNA damage response genes, reduces the phosphorylation level of CTD Ser2 in RNA polymerase II, and modulates biomarkers such as ATM, RAD51, γ-H2AX and cleaved PARP, thereby effectively inducing apoptosis and inhibiting proliferation of breast cancer cells. LL-K12-18 exhibits high target selectivity and serves as a research tool for studies on triple-negative breast cancer .
    LL-K12-18
  • HY-160096
    M3541

    		ATM/ATR Cancer
    M3541 is a potent, ATP-competitive and selective ATM inhibitor with an IC50 of 0.25 nM. M3541 shows remarkable selectivity against other protein kinases. M3541 suppresses double-strand breaks (DSB) repair and has antitumor activities .
    M3541
  • HY-157767
    Abd110

    		PROTACs ATM/ATR Cancer
    Abd110 (compound 42i) is a Lenalidomide-based PROTAC ATR kinase degrader. Abd110 selectively decreases ATR and phospho-ATR without affecting related kinases ATM and DNA-PKcs .
    Abd110
  • HY-144217
    SKLB-197

    		ATM/ATR Cancer
    SKLB-197 showed an IC50 value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo.
    SKLB-197
  • HY-119757
    Tyrphostin AG1433

    SU1433; AG1433

    		 PDGFR VEGFR Cancer
    Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation .
    Tyrphostin AG1433
  • HY-150617A
    (Rac)-Lartesertib

    (Rac)-M4076; (Rac)-ATM Inhibitor-5

    		 ATM/ATR STING PD-1/PD-L1 Cardiovascular Disease Inflammation/Immunology Cancer
    (Rac)-Lartesertib ((Rac)-M4076) is an isoform of Lartesertib (HY-150617). Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .
    (Rac)-Lartesertib
  • HY-174989
    ATM-IN-2

    		ATM/ATR Apoptosis Cancer
    ATM-IN-2 is a selective and orally active ATM inhibitor with an IC50 of 4 nM. ATM-IN-2 exhibits excellent kinase selectivity (>700-fold over PIKK family members). ATM-IN-2 exerts its anti-tumor effect by inhibiting ATM phosphorylation and the downstream signaling pathways (p53, H2AX), and promotes cell apoptosis. ATM-IN-2 can be used for the study of chemosensitizer candidate such as colon cancer .
    ATM-IN-2
  • HY-136835
    GJ071 oxalate

    		ATM/ATR Neurological Disease
    GJ071 oxalate induces ATM kinase activity in ataxia telangiectasia (A-T) cells carrying homozygous TGA or TAG stop codons .
    GJ071 oxalate
  • HY-153787
    ATM Inhibitor-6

    		ATM/ATR Cancer
    ATM inhibitor-6 (A-193) is a selective ATM kinase inhibitor. ATM inhibitor-6 can be used in cancer research .
    ATM Inhibitor-6
  • HY-112477
    Chk2-IN-1

    Hymenialdisine analogue-1

    		 Checkpoint Kinase (Chk) Choline Kinase Cancer
    Chk2-IN-1 (compound 1) is a potent and selective inhibitor of checkpoint kinase 2 (Chk2), with IC50s of 13.5 nM and 220.4 nM for Chk2 and Chk1, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM)-dependent Chk2-mediated radioprotection effect .
    Chk2-IN-1
  • HY-155091
    ATM Inhibitor-9

    		ATM/ATR Cancer
    ATM Inhibitor-9 (Compd 7a) is a potent ATM inhibitor with IC505 nM for ATM kinase, useful in cancer research .
    ATM Inhibitor-9
  • HY-144686
    ATM Inhibitor-3

    		ATM/ATR PI3K mTOR Cancer
    ATM Inhibitor-3 (compound 34) is a potent and selective ATM inhibitor, with an IC50 of 0.71 nM. ATM Inhibitor-3 shows inhibition of PI3K kinases family. ATM Inhibitor-3 exhibits favorable metabolic stability .
    ATM Inhibitor-3
  • HY-144687
    ATM Inhibitor-4

    		ATM/ATR PI3K mTOR Cancer
    ATM Inhibitor-4 (compound 39) is a potent and selective ATM inhibitor, with an IC50 of 0.32 nM. ATM Inhibitor-4 shows stronger inhibition of PI3K kinases family. ATM Inhibitor-4 shows a full inhibition of mTOR at 1 μM. ATM Inhibitor-4 exhibits favorable metabolic stability .
    ATM Inhibitor-4
  • HY-141478
    Antitumor agent-28

    		ATM/ATR Cancer
    Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity .
    Antitumor agent-28
  • HY-181786
    ATM-IN-13

    		ATM/ATR Cancer
    ATM-IN-13 (A36) is an orally active, selective ATM kinase inhibitor with a human IC50 of 0.3 nM. ATM-IN-13 blocks the ATM-mediated DNA double-strand break repair signaling pathway, reduces the phosphorylation levels of ATM and p53, and inhibits ATM-dependent DNA damage response. ATM-IN-13 can be used in the research of colorectal cancer .
    ATM-IN-13
  • HY-172247
    ATR-IN-31

    		ATM/ATR Cancer
    ATR-IN-31 is a selective ATR kinase inhibitor with an IC50 of 7 nM. ATR-IN-31 does not significantly inhibit ATM kinase activity. ATR-IN-31 inhibits viability of prostate cancer cells.ATR-IN-31 can be used for the research of prostate cancer .
    ATR-IN-31
  • HY-118911A
    ATM-IN-12

    		ATM/ATR Cancer
    ATM-IN-12 (example 1.1) is an ATM kinase inhibitor with an IC50 of 1.26 μM. ATM-IN-12 can be used for the study of ATM kinase mediated disease, including cancer .
    ATM-IN-12
  • HY-181060
    Apoptosis inducer 56

    		Apoptosis DNA/RNA Synthesis Caspase Bcl-2 Family MDM-2/p53 Cancer
    Apoptosis inducer 56 is an apoptosis inducer. Apoptosis inducer 56 induces DNA damage (upregulation of γH2AX and p-ATM expression) by minor groove binding. Apoptosis inducer 56 induces intrinsic apoptosis (upregulation of p53 and Bax/Bcl-2 ratio, cleaved caspase-7) via S-phase cell cycle arrest. Apoptosis inducer 56 shows selectivity for cancer cells over normal breast epithelial cells. Apoptosis inducer 56 can be used for the research of breast cancer .
    Apoptosis inducer 56
  • HY-182017
    ATR ligand 2

    		Ligands for Target Protein for PROTAC ATM/ATR Others
    ATR ligand 2 (Compound 26) is a ATR PROTAC ligand. ATR ligand 2 can be conjugated with E3 ligase Ligand (HY-W077589A) and linker to synthesize PROTAC ATR degrader-3 (HY-182016) .
    ATR ligand 2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: